Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Children whose cystic fibrosis is caused by a rare gene variant are excluded from a new treatment which could potentially ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

RTE Room to Improve viewers were moved to tears tonight as an old home was transformed into something “amazing” for Cystic ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Dermot Bannon joined forces with Julian Benson to create a 'home away from home' in Dublin for cystic fibrosis patients and ...

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi to ... and provides the first treatment option that tackles the underlying cause of CF in patients ...

RTE's Dermot Bannon teamed up with TV personality and dancer Julian Benson to provide a 'home away from home' for people ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...